1-3 of 3
Mark A. Ahlman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30 + lymphomas: results of a phase 1 trial

Clinical Trials & Observations
Jennifer N. Brudno, Danielle A. Natrakul, Jeremiah Karrs, Nisha Patel, Roberto Maass-Moreno, Mark A. Ahlman, Lekha Mikkilineni, Jennifer Mann, David F. Stroncek, Steven L. Highfill, Genevieve C. Fromm, Rashmika Patel, Stefania Pittaluga, James N. Kochenderfer
Journal: Blood Advances
Blood Adv (2024) 8 (3): 802–814.
https://doi.org/10.1182/bloodadvances.2023011470
Published: 2024
Includes: Supplemental data
Journal Articles

Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy

Clinical Trials & Observations
Elizabeth M. Holland, Bonnie Yates, Alex Ling, Constance M. Yuan, Hao-Wei Wang, Maryalice Stetler-Stevenson, Michael LaLoggia, John C. Molina, Daniel A. Lichtenstein, Daniel W. Lee, John A. Ligon, Haneen Shalabi, Mark A. Ahlman, Nirali N. Shah
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2167–2182.
https://doi.org/10.1182/bloodadvances.2021006035
Published: 2022
Includes: Supplemental data
Journal Articles

Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy

Clinical Trials & Observations
Nirali N. Shah, Haiying Qin, Bonnie Yates, Ling Su, Haneen Shalabi, Mark Raffeld, Mark A. Ahlman, Maryalice Stetler-Stevenson, Constance Yuan, Shuang Guo, Siyuan Liu, Stephen H. Hughes, Terry J. Fry, Xiaolin Wu
Journal: Blood Advances
Blood Adv (2019) 3 (15): 2317–2322.
https://doi.org/10.1182/bloodadvances.2019000219
Published: 2019